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Neuropathic pain (NP) is associated with profound gene expression alterations within the nociceptive
system. DNA mechanisms, such as epigenetic remodeling and repair pathways have been implicated
in NP. Here we have used a rat model of peripheral nerve injury to study the effect of a recently devel-
oped RARb agonist, C286, currently under clinical research, in NP. A 4-week treatment initiated 2 days
after the injury normalized pain sensation. Genome-wide and pathway enrichment analysis showed
that multiple mechanisms persistently altered in the spinal cord were restored to preinjury levels
by the agonist. Concomitant upregulation of DNA repair proteins, ATM and BRCA1, the latter being
required for C286-mediated pain modulation, suggests that early DNA repair may be important to
prevent phenotypic epigenetic imprints in NP. Thus, C286 is a promising drug candidate for neuro-
pathic pain and DNA repair mechanisms may be useful therapeutic targets to explore.
INTRODUCTION
The identification of an effective therapy for neuropathic pain (NP) has been challenging owing to three
main factors: first, multiple mechanisms are involved for which no single multifactorial drug has been devel-
oped; second, differences in cellular and molecular mechanisms between animals and humans have
hampered progress; and third, no single ‘‘switch’’ has been identified that could curtail the pathological
cascade and provide a therapeutic target (Borsook et al., 2014; Gereau et al., 2014).
There are two primary features of NP: (1) hyperalgesia, increased pain from a stimulus that usually evokes
pain; and (2) allodynia, pain due to a stimulus that usually does not provoke pain (Jensen and Finnerup,
2014). It appears that there are at least two distinct aspects to the development of these features: periph-
eral sensitization, involving changes in the threshold of peripheral nociceptors including possible sponta-
neous firing, and central sensitization, in which there are changes in the responsiveness at the central syn-
apses relaying nociception, especially in the dorsal horn of the spinal cord. There is still debate about the
importance of central sensitization and whether it relies, for its maintenance, on the peripherally sensitized
input (Meacham et al., 2017).
Although it is generally agreed that there are a profusion of gene expression changes in NP (Descalzi
et al., 2015), the underlying general mechanism by which they are induced is still uncertain. One sug-
gestion is that the underlying cause is an inflammatory reaction to injury (Ellis and Bennett, 2013),
which in turn causes DNA damage (Kelley and Fehrenbacher, 2017). Madabhushi and colleagues (Ma-
dabhushi et al., 2015) have shown that even neuronal activity can be sufficient to induce DNA damage
(double-strand breaks, DSBs), particularly in the promoter region of early response genes, causing
their upregulation, and this, in turn, can alter the expression of late response genes, such as brain-
derived neurotrophic factor (bdnf). Their experiments supported the conclusion that DNA DSB forma-
tion was necessary and sufficient to induce early response gene expression and that DNA repair could
reverse the gene expression. Similarly, Fehrenbacher and her colleagues showed that enhanced DNA
repair could reverse the changes in neuronal sensitivity that they observed (Kelley and Fehrenbacher,
2017).
In terms of cellular responses, converging lines of evidence support that a specific microglia inflammatory
phenotype characterized by the de novo expression of the purinergic receptor P2X4 is critical to the554 iScience 20, 554–566, October 25, 2019 ª 2019 The Author(s).
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induction of core pain signaling, mediated by the release of BDNF, which produces hypersensitivity in noci-
ceptive neuron in the spinal dorsal horn.
It is not understood how this specific spinal microglia phenotype (P2X4R+) that arises during the acute
stage following peripheral nerve injury (PNI) results in imprinting of the chronic and persistent changes
in the spinal nociceptive networks after the acute inflammatory response has subsided (Beggs et al.,
2012; Ulmann et al., 2013). Epigenetic alterations in spinal microglia during the acute inflammatory
response presents a favorable paradigm for the imprinting mechanism driving chronicity of the pain state
(Denk et al., 2016) because of the high transcriptional activity induced by the inflammatory response and
the associated increase in DNADSB (Marnef et al., 2017). Indeed, a wealth of data suggests that the fragility
of actively transcribing loci is intertwined with genomic changes that are linked to altered cellular function
and disease (Alt and Schwer, 2018; Fong et al., 2013; Puc et al., 2017; Sharma et al., 2015; Su et al., 2015).
This raises the question: could this represent a biological switch and thus a therapeutic target, whereby
inducing an increase in DNA repair following PNI would preserve the genomic landscape of the spinal mi-
croglia during acute activation, when high transcriptional activity is expected, and thus provide an effective
way to target NP?
Here we show that a novel drug, Retinoic Acid Receptor (RAR)b agonist, C286 (Goncalves et al., 2019a),
prevents NP by restoring pathways that are chronically altered in the spinal cord (SC) after PNI and that
this is associated with a switch in the spinal microglia P2X4R phenotype via a mechanism dependent on
the breast cancer susceptibility gene 1 (BRCA1). Since the retinoic acid (RA) pathway is highly conserved
between species (Rhinn and Dolle, 2012), our findings support C286 as a plausible impending therapy
for NP and provide evidence that DNA repair mechanisms are disease-modifying therapeutic targets.RESULTS
C286 Modulates Multiple Pathways Chronically Altered after Spinal Nerve Ligation
RA has been shown to inhibit TNFa and iNOS in reactive microglia (Dheen et al., 2005), and our previous
work shows that stimulation of RARb hampers astrogliosis after spinal cord injury (Goncalves et al., 2015).
We therefore hypothesized that a novel drug RARb agonist, C286, may modulate the inflammatory
response of activated microglia to prevent the onset of the microglia-neuron alterations that underly
NP. Because we specifically wanted to investigate the effect of the drug in P2X4R+ microglia and this
phenotype has been shown to evoke spinal mechanisms of nerve injury-induced hypersensitivity predom-
inantly in males but not in female rats (Mapplebeck et al., 2018), we chose male rats only for this study.
Using an established rat model of NP, L5 spinal nerve ligation (SNL) (Kim andChung, 1992), we assessed the
effect of C286 given orally for 4 weeks on mechanical and thermal pain thresholds over the treatment
period. C286 treatment reversed the hypersensitivity caused by SNL to levels comparable with the preinjury
state (Figures 1A–1E). We next used co-expression analysis of genome-wide RNA sequencing of dorsal
horns isolated from non-injured and L5-SNL rats that had been treated with vehicle or C286 to delineate
pathways that may have a role in the formation of the long-term hyperalgesia-related imprint in the SC (Fig-
ures 1F and 1G). The non-injured tissue was used to establish the normal gene expression with and without
C286, whereas the L5-SNL vehicle-treated tissue served as a platform to identify gene expression patterns
that were induced by the surgery and peripheral lesion and was used as a control to directly compare gene
expression changes that were altered solely owing to the drug treatment. Through analysis of co-expres-
sion paths we identified a variety of genes involved in a broad range of cellular functions, including neural
transmission, cell adhesion, growth cone and synapse formation, and mitochondrial function (Figure 1H).
Among differentially expressed transcripts we identified genes associated with pain-related pathways,
altered in different models of pain, or encoding products interacting with proteins involved in pain-related
pathways (Figures S1 and S2 and Table S1 [related to Figures 1 and 2]. Figure S2 and Table S1 are available
on the Mendeley repository https://doi.org/10.17632/kjvs5vgkbf.1DOI). We observed that C286 upregu-
lates pathways that are compromised in NP: cell adhesion (Patil et al., 2011), growth cone (Hur et al.,
2012), and gap junction (Wu et al., 2012) (Figure S2, https://doi.org/10.17632/kjvs5vgkbf.1DOI) and
downregulates pathways back to non-injured baseline that are upregulated in NP: long-term potentiation
(Ruscheweyh et al., 2011), WNT (Zhang et al., 2013), MAPK (Ji et al., 1999; Jiang et al., 2008; Jin et al., 2003;
Kawasaki et al., 2004; Obata and Noguchi, 2004; Song et al., 2005; Zhang and Yang, 2017), erbB (Calvo
et al., 2011), TRP channels (Moran and Szallasi, 2018), and cAMP (Edelmayer et al., 2014) (Figures 2A, 2B,
and S2 and Table S1, available on the Mendeley repository https://doi.org/10.17632/kjvs5vgkbf.1DOI).iScience 20, 554–566, October 25, 2019 555
Figure 1. C286 Modulates Multiple Pathways Chronically Altered after SNL
(A–E) (A) Schematic of experimental paradigm. L5-SNL, spinal nerve ligation; SC L5 ipsi (spinal cord, L5 level ipsilateral to injury) indicates the area where
tissue analysis was carried out and is delineated as a red square in subsequent figures. Measurement of mechanical and thermal sensitivities shown as paw
withdrawal (PW) in grams (g) or seconds (sec), by (B) von Frey filaments, (C) hot plate, (D) cold plate, (E) and Randall Selitto test in vehicle (n= 8) or C286 (n= 8).
Data shown as Mean G SEM. Two-way ANOVA with Pairwise Multiple Comparison Procedures (Holm-Sidak method). **p% 0.01, ***p% 0.001.
(F–H) Gene co-expression analysis assessed in the SC from L5-SNL rats and non-injured rats, treated with vehicle or C286. (F) Differential gene expression
analysis relative to the sample non-injured + vehicle. (G) Differentially expressed genes are classified by their co-expression paths assessed after injury and
injury + vehicle or C286 treatment. (H) Gene ontology analysis performed per co-expression path. The heatmap illustrates the GO enrichment confidence.Because of their prominent role in the regulation of nociceptive signal perception we focused on theMAPK
and WNT pathways for further analysis.
WNT signaling in the SC stimulates the production of proinflammatory cytokines through the activation of
WNT/FZ/b-catenin pathway in nociceptive neurons (Tang, 2014; Zhang et al., 2013). MAPK is activated in
spinal microglia after PNI and, upon nuclear translocation, activates transcription factors that promote
dynamic nuclear remodeling. This results in the transcription and translation of proteins that prolong
potentiation and decrease the threshold for receptor activation, the molecular underpinnings of clinical al-
lodynia (Wahezi et al., 2015).
TheWNT receptor Frizzled 10 (FZD10) and the death domain-associated protein, Daxx, components of the
WNT and MAPK pathways, respectively, were highlighted by our co-expression analysis owing to the
magnitude of their expression changes between vehicle and C286-treated L5-SNL rats. FZD10 has been556 iScience 20, 554–566, October 25, 2019
Figure 2. C286 Regulates Inflammatory and DNA Repair Pathways
(A) Genes were classified on the basis of their co-expression behavior over the various conditions. C286 downregulated 165 genes that had been
upregulated by the injury.
(B) GO terms associated to the co-expressed genes are displayed on the basis of their confidence (10*log10[p value]), red arrows highlight the MAPK and
WNT pathways.
(C) Diagram of experimental design.
(D–G) (D and E) Representative images and quantification of FZD10 (scale bar, 100 mm and 20 mm for higher-magnification insets) and (F and G) of Daxx
expression in microglia (Iba1) and neurons (bIII tubulin) in the SC at the end of the treatment period (scale bar, 50 mm). Two weeks after injury, a sub-set of
vehicle- and C286-treated rats was used for immunohistological analysis (n = 3 per treatment group) and for RT-qPCR (n = 3 per treatment group).
(H–K) (H and I) Levels of P2X4R+ microglia (highlighted by arrows in the merged upper panel, scale bar, 30 mm) and (J and K) BDNF (in neurons and microglia)
in the SC (scale bar, 30 mm).
(L and M) (L) Images showing BRCA1 expression in the same area (insets show higher magnification of BRCA1 in nuclei, scale bar, 100 mm) and (M)
quantification by RT-qPCR.
(N–P) Expression and quantification of BRCA1 and pATM in spinal microglia (scale bar, 20 mm).
(Q and R) Expression and quantification of gH2AX (scale bar, 100 mm).
In E, G, I, K, O, P, and R, data are shown as MeanG SEM of fluorescence intensity (FI) in arbitrary units (a.u.). Student’s t test, **p% 0.01, ***p% 0.001, n = 4
(E and G) or n = 3 (I, K, M, P, and R) per group, five sections per animal).
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shown to be expressed in pain pathways, including dorsal horn neurons (Hu et al., 2009), and Daxx (which is
ubiquitously expressed) has a well-established role in apoptosis but can also participate in numerous addi-
tional cellular functions as a mediator of protein interactions (Lindsay et al., 2008), as a potent suppressor of
transcription (Takahashi et al., 2004), and as a modulator of cargo-loaded vesicles transport, an important
emerging factor in neuron-glia cross-talk during NP (McDonald et al., 2014; Shiue et al., 2019). Immunohis-
tochemistry confirmed downregulation of FZD10 and Daxx protein levels by C286 (see Figures 2C–2G).C286 Regulates Inflammatory and DNA Repair Pathways
Inflammation can be a common trigger of MAPK andWNT pathways (Roubert et al., 2017), and hence their
downregulation by the agonist at 28 days post injury could indicate an earlier resolution of the inflammatory
state. A subtype of purinergic receptor, P2X4R, regulates microglial activation (Ulmann et al., 2013), and its
upregulation in spinal microglia has been proposed as an important inflammatory switch that is necessary
and sufficient for subsequent pain hypersensitivity, acting via BDNF release and subsequent uptake by the
nociceptive neurons in the dorsal horn (Beggs et al., 2012). We therefore assessed the effect of C286 on the
expression of P2X4R in spinal microglia and BDNF in microglia and neurons in the dorsal horn at 14 days
post PNI, a time point that reflects the interphase between the beneficial acute microglia response and the
switch to the perpetuated reactive state that could trigger the chronic pain. We found both to be signifi-
cantly lower compared with vehicle-treated rats (Figures 2H–2K). Similarly, other inflammatory mediators
and growth factors associated with NP, such as NGF, TNFa, and TNFR1 (Amaya et al., 2013), were also
downregulated in the agonist-treated SCs (Figures S3A–S3H, related to Figure 2). We did not find their
mRNAs upregulated at 4 weeks in the vehicle-treated L5-SNL rats, in agreement with other studies in
the same injury model that report only a temporary post-lesion increase in these proteins (de Jager
et al., 2011).
Next, we wanted to ascertain if the switch in the microglia phenotype from predominantly P2X4R+ to
P2X4R correlated with higher DNA repair efficiency. We reasoned that an increase in DNA repair during
the acute phase of microglia activation (Ellis and Bennett, 2013), when transcriptional changes are occur-
ring during adaptation to the injury, could prevent the occurrence of transcriptional imprints that
contribute to chronic pain. This would favor regaining the non-activated genomic state. The involvement
of the DNA repair protein BRCA1 in spinal microglia after injury has been recently described where an initial
physiological attempt to repair is seen by an increase in BRCA1 expression, but that is not sustained
beyond 72 h post injury (Noristani et al., 2017). A link between BRCA1 and RA signaling has been
highlighted by previous studies; genome-wide analysis suggests a role for BRCA1 in transcriptional co-acti-
vation to RA (Gardini et al., 2014) and RAR/RXR-mediated transcription requires recruitment of the BRCA1
co-repressor C-terminal-binding protein 2 (CtBP2) (Bajpe et al., 2013), which could result in the elevation of
BRCA1 transcription, a mechanism already described for estrogen (Di et al., 2010).
To assess if C286 could be prolonging BRCA1 expression, we measured BRCA1 levels in the dorsal horn by
western blotting (Figures 2L and 2M) and by immunochemistry in spinal microglia and found that C286
significantly increased BRCA1 levels, predominantly in the nucleus (Figures 2L, 2N, and 2O).C286 Regulates DNA Damage in Microglia via BRCA1 and ATM Pathways
Cellular responses to DNA damage are mediated by an extensive network of signaling pathways. The
ataxia telangiectasia mutated (ATM) kinase responds specifically to DNA DSBs, which are associated
with signal-induced transcriptional changes. ATM can be activated by RA (Fernandes et al., 2007) and
suppresses MAPK pathways via a DSB-induced response whereby MKP-5 is upregulated and dephos-
phorylates and inactivates the stress-activated MAP kinases JNK and p38 (Bar-Shira et al., 2002). We
therefore assessed ATM phosphorylation levels in the SCs and found that C286 significantly increased
pATM in spinal microglia (Figures 2N and 2P). Concomitantly, we observed a significant decrease in
the ATM target and DNA damage marker gH2AX (Sharma et al., 2012) (Figures 2Q and 2R). To
confirm if the modulation of these two DNA repair mechanisms was a direct effect of the agonist
in microglia, we treated lipopolysaccharide-activated microglia cultures with vehicle, C286, an ATM
inhibitor (KU55933) alone, or with C286 and found that C286 significantly increased BRCA1 and
pATM and significantly decreased gH2AX compared with vehicle. Importantly, the effect on pATM
was completely abrogated in the presence of KU55933, suggesting a direct effect on ATM auto-phos-
phorylation (Figures 3A–3H).558 iScience 20, 554–566, October 25, 2019
Figure 3. C286 Regulates DNA Damage in Microglia via BRCA1 and ATM Pathways
(A) Diagram showing microglia culture conditions and markers assessed.
(B–E) (B and C) BRCA1 and (D and E) gH2AX expression and quantification in microglia cultures.
(F) Diagram showing the experimental design.
(G and H) Expression and quantification of pATM in nuclei in the different culture conditions. Scale bars, 15 mm. Data showMean FIG SEM from three independent
experiments (C and E), Student’s t test, *p% 0.05 and (H) one-way ANOVA with Pairwise Multiple Comparison Procedures (Tukey Test), ***p% 0.001.BRCA1 Is a Downstream Target of C286 in NP Modulation
To functionally validate the RARb-BRCA1 pathway in pain we used lentiviral transduction of shRNA BRCA1
in our rat model of NP. Treatment with C286 yielded no significant improvement in the pain thresholds
when BRCA1 was ablated (Figures 4A–4C). Confirmation of effective lentiviral transduction was obtained
by immunochemistry (Figures 4D–4F). Further analysis of BRCA1 expression in spinal microglia showed
that this was significantly decreased in LV/BRCA1shRNA + C286-treated rats compared with LV/sc +
C286 (Figures 4G–4I), and the inverse was seen with gH2AX (Figures 4J–4L). In agreement with the pain
behavioral tests, we found that the calcitonin gene-related peptide (CGRP), which contributes to the hyper-
sensitization (Iyengar et al., 2017), was significantly upregulated in the dorsal horn (predominantly laminae
I-III) of LV/BRCA1shRNA + C286-treated rats (Figures 4M and 4N).
To establish if there was a direct link between BRCA1 and themicroglia activation, we assessed the levels of
P2X4R in spinal microglia and found a significant increase in the LV/BRCA1shRNA + C286-transduced ratsiScience 20, 554–566, October 25, 2019 559
Figure 4. BRCA1 Is a Downstream Target of C286 in NP Modulation
(A) Schematic of experimental paradigm.
(B and C) (B) Measurement of thermal and mechanical sensitivities by von Frey filaments (C) and hot plate in vehicle (n = 6) or C286 (n = 6). Data shown as
Mean G SEM. Two-way ANOVA with Pairwise Multiple Comparison Procedures (Holm-Sidak method). ***p% 0.001.
(D) Co-labelling of GFP and Iba1 (scale bar, 20 mm), and GFP and BRCA1 in LVsc + C286- and LVBRCA1shRNA + C286-treated rats (scale bar, 100 mm).
(E–H) (E and F) Western blots and quantification of BRCA1 in L5-SNL rats transduced with LV/SC + C286 (n = 3) or LV/BRCA1shRNA + C286 (n = 3). Student’s
t test. *p% 0.05 (G) Immunohistological confirmation of LV transduction (scale bar, 20 mm), (H) higher-magnification inset shows BRCA1 in microglia in an
LV/Sc + C286-treated rat (scale bar, 10 mm).
(I) Quantification of BRCA1 in microglia.
(J and K) Expression and quantification of gH2AX (scale bar, 20 mm), (L) higher-magnification inset shows gH2AX in microglia in an LV/BRCA1shRNA +
C286-treated rat (scale bar, 10 mm).
(M and N) Expression and quantification of CGRP in laminae I–III of the dorsal horn (scale bar, 100 mm).
(O and P) Expression and quantification of P2X4R (scale bar, 100 mm). Inset shows higher-magnification image (scale bar, 20 mm) Data are shown as
Mean +SEM of FI. Student’s t test, **p% 0.01, ***p% 0.001 (n = 3 per group, 5 sections per animal).
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Figure 5. BRCA1 Influences Inflammatory Mechanisms in NP
(A) Diagram of the experimental design.
(B–G) (B) Immunostaining of spinal microglia and NGF, (D) TNFa, and (F) TNFR1 in LV/sc + C286- and LV/BRCA1shRNA + C286treated rats (scale bars,
30 mm). Quantification of FI for (C) NGF, (E) TNFa, and (G) TNFR1. Data show Mean FI G SEM, Student’s t test, ***p % 0.001 (n = 3 per group, 5 sections
per animal).(Figures 4O and 4P). This effect was also seen for NGF, TNFa, and TNFR1 (Figures 5A–5G), indicating that
an inflammatory environment was still present in the SC. Concurrent protein expression analysis of BDNF
and the components of the MAPK and WNT pathways (FZD10 and Daxx), which had been modified by the
agonist in L5-SNL non-transduced rats (see Figure 2), showed a significant increase with the suppression of
BRCA1 despite the agonist treatment (Figures 6A–6H).DISCUSSION
Collectively, we show that C286 generates a ‘‘repair proficient’’ environment that may influence epige-
netic modification of some enhancers in microglia, resetting the transcriptome toward a resting state
after injury and thus reducing the long-term transcription of NP-associated genes. C286 modulates
DNA repair mechanisms involving BRCA1 and ATM in spinal microglia, the former being directly
linked to the P2XR4 phenotype and the development of NP. This supports the concept that transcrip-
tion-induced persistent damage that is inefficiently repaired could chronically alter the epigenetic
landscape, in line with the emerging importance of BRCA1 in neurodegenerative diseases (Mano
et al., 2017; Suberbielle et al., 2015). Current therapeutic strategies generally aim at a single molec-
ular target. These are yielding unsatisfactory results and are thus giving ground to a multifactorial
approach targeting the numerous pathways involved, one possibility being to influence DNA repair
mechanisms (Kelley and Fehrenbacher, 2017). Here we show that C286 has multiple effects on path-
ways that contribute to the chronicity of the neuronal sensitivity and thus might prove a more success-
ful approach for the treatment of NP.RARb Signaling and WNT/FZD Signaling
We found that the WNT pathway is one of the most significantly downregulated pathways by the agonist.
The importance of the WNT/FZD signaling in signal transduction and synaptic plasticity alterations, which
are essential to SC central sensitization after nerve injury, has been documented before (Zhang et al.,
2013; Zhao and Yang, 2018). It is thought that WNT/FZD/b-catenin signaling contributes to the onset
and persistence of pain after nerve injury, through activation of signaling pathways that recapitulate devel-
opment, such as axon guidance, synaptic connection, and plasticity in the spinal cord. Spinal blockade of
WNT signaling can inhibit the production and persistence of PNI-induced NP and prevent upregulation of
the NR2B receptor and the subsequent Ca2+-dependent signals CaMKII, Src/Tyr418, pPKCg, ERK, and
cAMP response element-binding protein within the SC pain pathways (Zhang et al., 2013). Curiously,iScience 20, 554–566, October 25, 2019 561
Figure 6. BRCA1 Is Necessary for C286-Mediated Regulation of Pain
(A) Diagram of the experimental design.
(B–D) (B and C) Immunostaining of spinal microglia for BDNF (scale bar, 50 mm) and its quantification. (D) Western blots of
spinal cords for BDNF. Student’s t test, n = 3 per group, ***p% 0.001.
(E–H) (E and F) Expression and quantification of FZD10 (white arrows show colocalization with Iba1 and black arrows with
bIII tubulin) and (G and H) Daxx in spinal neurons andmicroglia of LV/sc + C286- and LV/BRCA1shRNA+C286-treated rats
(insets show its predominant nuclear localization). Scale bars, 100 mm for E and G. Data show Mean FIG SEM, n = 3 per
treatment group, 5 sections per animal. Student’s t -test, **p% 0.01, ***p% 0.001.
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we found that C286 suppresses WNT/FZD signaling and upregulates pathways involved in regeneration,
which are also important during development. This may seem an incongruence, but we must consider that
the overall biological effect is determined by a network of interacting pathways. WNT is known to interact
with ephrinB-EphB receptor signaling, which also activates various developmental processes of the
nervous system in response to nerve injury (Han et al., 2008; Song et al., 2008) and is thought to contribute
to pain enhancement. These interactions may result in an exacerbation of neurochemical signs within
development pathways that trigger and sustain pain pathways. Therefore, it is likely that the C286-medi-
ated stimulation of the regeneration and development pathways is quite different, both qualitatively and
quantitatively, because C286 upregulates transcription of these pathways to preinjury levels but not
beyond. This promotes the restoration of homeostasis and prevents activation of pathways that sustain
pain.RARb and MAPK/Daxx Signaling
It is interesting that Daxx showed the highest downregulation within the MAPK pathway. Daxx is asso-
ciated mostly with triggering apoptotic pathways that result in cell death and/or senescence. The
agonist prevented the upregulation of Daxx in response to the injury and concomitantly upregulated
various other pathways that are associated with normal cellular functions: cell-adhesion, mitochondria
function, etc. The counterpart scenario, i.e., the downregulation of these pathways in the vehicle-
treated rats, possibly reflects a state of compromised cellular functions in the SC. Therefore, it seems
that Daxx could be an important contributor to cell fate in PNI-induced NP in the SC.
We found that RARb activation downregulates TNF-a, which is one of the cytokines that induces
phosphorylation and stabilization of Daxx through ASK1 activation. This is essential for activation of
the pain signaling pathways, JNLK and p38 (Chang et al., 1998; Ichijo et al., 1997; Ji et al., 2009).
Thus, it is possible that the marked downregulation of Daxx by C286 is in part a consequence of
the agonist’s anti-inflammatory effect. Similarly, the prevention of the reactive microglia P2X4R pheno-
type could be a direct consequence of a milder inflammatory milieu facilitated by the acute agonist
action. Nonetheless, the overall effect of C286 cannot be justified entirely and solely by an initial anti-
inflammatory effect. If that was the case, then anti-inflammatory treatment would be a successful ther-
apeutic approach. Arguably, it is a combination of different mechanisms directly and indirectly
affecting various intracellular functions: DNA repair, transcription, organelle transport, energy supply,
and secretion of signaling molecules, which contributes to the RARb modulation of NP.RARb and the Extracellular Matrix
C286 also induced an upregulation of cell adhesion and cell junction pathways. This is noteworthy because
adhesion proteins, which normally build and modify synapses, also participate in different aspects of syn-
aptic and circuit reorganization associated with NP (Dina et al., 2004).C286 as a Promising Transcriptional Drug
We challenge the dogma that nuclear receptor agonists are unpromising therapeutic targets. Nuclear
receptor signaling has been overlooked as a therapeutic avenue. Although nuclear receptor signaling
regulates many pathways, it is thought that some of these might be detrimental to the cells casting
doubt on the overall biological effect. However, effective therapies need to be multifactorial, especially
if they are aimed at chronic conditions in which a myriad of cellular functions has been altered. Ret-
inoic acid modulates transcription and exerts its biological activity via the nuclear receptor RAR/RXR
heterodimers, of which three isoforms have been identified (a,b,g) (reviewed in Maden, 2007). Each iso-
form differs in spatial expression and yields different biological responses. In this regard, it is therefore
beneficial to use specific receptor agonists targeted to the particular receptor that will induce the
desired/anticipated effect. Because RXRs are promiscuous receptors and partner with various other nu-
clear receptors integrating their signaling pathways (Lefebvre et al., 2010), they are less attractive as
drug targets. We have demonstrated target engagement previously and shown the upregulation of
RARb in response to treatment with specific RARb agonists (Goncalves et al., 2018, 2019b). Our
work illustrates an example of where a nuclear receptor agonist provides an effective treatment for
a chronic condition without induction of detrimental pathways. C286 is currently undergoing a phase
1 trial (ISRCTN12424734) and can rapidly progress to further clinical testing proving an attractive ther-
apeutic avenue to explore for NP.iScience 20, 554–566, October 25, 2019 563
DNA Damage Pathways and Future Therapeutic Avenues
DNA damage has recently been proposed to play an important role in transcriptional regulation. Here we
show that it is involved in setting an inflammatory state in spinal microglia that triggers NP. Our results
demonstrate a novel role for BRCA1 in NP. BRCA1 is a DNA repair protein, best known for its association
with breast cancer. We demonstrate that, by increasing DNA repair via BRCA1, NP can be prevented. This
revolutionizes the therapeutic exploration for NP, shifting its focus from targets whose modification pro-
vides symptomatic and temporary amelioration to a more permanent disease-modifying target: DNA
repair. Recovery of normal cellular functions through effective and timely DNA repair might be a successful
prophylactic and/or therapeutic approach that is extendable to other chronic conditions similarly associ-
ated with an inflammatory etiology. Exploring other drugs that, like C286, modulate BRCA1 and identifying
other key DNA repair mechanisms could be a step change in therapeutic development.
Limitations of the Study
This study was conducted in male rats only and as such does not address the sexual dimorphism in pain.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.09.020.
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 Figure S1. Transcriptomics analysis of spinal cord samples issued from animals under 
different conditions 
A, Summary of the number of DNA sequenced reads obtained per sample as well as the fraction 
retained after alignment to the Rattus norvegicus reference Genome. B, Boxplots depicting the 
read counts per gene prior or after quantile normalization. C, Volcano plot illustrating the 
fraction of differentially expressed genes (rel. to non-injured + vehicle condition), as defined 
by a two-fold change criterion, and their related confidence (p-value). 
 
Figure S2. Gene Ontology (GO) enrichment analysis on co-expressed genes 
(http://dx.doi.org/10.17632/kjvs5vgkbf.1DOI) 
Considering 3 differentially expressed conditions (non-injured + C286; injured + vehicle; 
injured + C286) and three gene expression states (induced, repressed and non-differentially 
expressed), a total of 26 combinatorial gene co-expression events are theoretically possible. 
Genes were classified on the basis of their co-expression behavior over the various conditions.  
GO terms associated to the co-expressed genes are displayed on the basis of their confidence 
(-10*log10(p-value), as inferred by the DAVID bioinformatics resources (Huang da et al., 
2009). Co-expression path 1 is shown here, all the other paths are available in 
(http://dx.doi.org/10.17632/kjvs5vgkbf.1DOI). 
 
Figure S3. Modulation of TNF, TNFR1 and NGF by C286 
a, Diagram of the experimental design. b-d, Immunostaining and quantification of TNF and 
TNFR1 by IF (scale bars are 100m and 50 m for insets) and by e,f,  RT-qPCR. Student’s t-
test, **p ≤ 0.01, ***p ≤ 0.001, (n= 3 per group).  g, NGF expression in spinal neurons and 
microglia (scale bar is 30m) and h, quantification of total FI. Data shows Mean FI ± SEM. 
Student’s t-test, **p ≤ 0.01, ***p ≤ 0.001, (n= 3 per group, 5 sections per animal). 
 Table S1. Summary of the GO terms for all 20 co-expression paths 
(http://dx.doi.org/10.17632/kjvs5vgkbf.1DOI)   
The p-value is expressed in "-10*log10(p-value)" and for each path it is indicated their 
corresponding status (i.e. [0][1][0] indicated the expression status for [Non-
Injured+C286][Injured+Veh][Injured+C286]). 
 
Transparent Methods 
Rats and animal procedures 
All procedures were in accordance with the UK Home Office guidelines and Animals 
(Scientific Procedures) Act of 1986. Male Sprague Dawleys rats, weighing 220-250 grams 
were used throughout the study. All animal care and experimental procedures complied with 
the Animals (Scientiﬁc Procedures) Act, 1986 of the UK Parliament, Directive 2010/63/EU of 
the European Parliament and the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996). Animal 
studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; 
McGrath and Lilley, 2015). All surgery, behavioural testing and analyses were performed using 
a randomized block design and in a blinded fashion. Allocation concealment was performed 
by having the treatment stocks coded by a person independent of the study. Codes were only 
broken after the end of the study. 
Animals were housed in groups of three to four in Plexiglas cages with tunnels and bedding, 
on a 12:12 h light/dark cycle and had access to food and water ad libitum. Experimental 
neuropathy was induced by an L5 spinal nerve ligation (Bennett et al., 2003) (L5 SNL-2 week 
analysis; n= 6 per treatment group; L5 SNL- 4 week analysis n= 8 per treatment group; L5 
SNL with lentivirus; n=6 per treatment group). Briefly, rats were anesthetized via 
intraperitoneal injection of 0.25 mg kg−1 medetomidine/60 mg kg−1 ketamine solution, 
following which the vertebral transverse processes were exposed via a small skin incision and 
 retraction of the paravertebral musculature. The L6 transverse process was partially removed 
and the L5 spinal nerve was identified, tightly ligated, and sectioned 1–2 mm distal to the silk 
ligature. During the surgery, the rats were placed on a controlled heating pad to maintain 
temperature at 37 ± 1°C. After the surgery, the rats were hydrated with physiological saline (2 
mL, s.c.). Anesthesia was reversed with an intra muscular (IM) injection of 0.05 ml (1 mg/kg) 
atipamezole hydrochloride (Antisedan®; Pfizer Animal Health, Exton, PA). Animals were kept 
in a heated recovery box until fully conscious and analgesia (buprenorphine, 0.01 mg/ kg, 
subcutaneously) was given after suturing and recovery. All the rats survived this surgery. 
For BRCA1 loss of function studies, at the time of the L5 SNL, 5 μl of lentivirus (titer: 
3.67 × 108 TU/ml), either Brca1 Rat shRNA Lentiviral Particle, sequence, 
TACACAGCCTGGTGTCTCTAAGCAGAGTG, or scrambled, sequence, 
GCACTACCAGAGCTAACTCAGATAGTACT (TL709162V, Origene) was injected 
manually into the spinal cord at the level of L5, using a 20 μl Hamilton syringe at 0.5 μl min− 1 
and the needle was left in place for the following 5 minutes to limit diffusion through the needle 
tract.  
 
Drug treatments and tissue processing for in vivo studies 
Rats were treated with vehicle or a novel selective RAR agonist, C286 (Goncalves et al., 
2019a) (synthesized by Sygnature Chemical Services, Nottingham, UK), given by oral gavage 
(po) three times a week for four weeks at 3mg/kg. C286 has a high potency at RAR (similar 
potency to all-trans-retinoic acid) and behaves as a full agonist showing an EC50 of 1.94 nM at 
the mouse RAR receptor and a selectivity for RAR over RAR of 13.4, with selectivity for 
RAR over RAR being 5.6-fold (Goncalves et al., 2019a). 
After defined survival times, animals were killed by terminal anesthetization and transcardially 
perfused with 4% paraformaldehyde, for immunohistochemistry or ice-cold PBS, for mRNA 
 extraction and Western blotting. The lumbar spinal cords were excised, rapidly removed and 
the tissue corresponding to L5 spinal cord was isolated.  For immunohistochemistry, the tissue 
was post-fixed with 4% PFA for at least two days at room temperature before being embedded 
in paraffin wax. Five m longitudinal or transverse sections cut throughout each block. Sets of 
consecutive sections, comprising the L5 lumbar spinal cord were taken and used for 
immunohistochemical analysis. For mRNA extraction and Western blotting, L5 spinal cords 
were bi-dissected into ipsi and contralateral side to the injury, and tissue was snap frozen in 
liquid nitrogen and kept at -80 0C until further use. 
 
Behavioural tests 
Pain thresholds were measured according to the methods described below. Baseline recordings 
were taken at 1 day prior to surgery and at 1, 6, 9, 16, 23 and 28 days after surgery for L5 SNL 
experiment and at 1, 7, 14, 21 and 28 days for the L5 SNL lentivirus study. 
 
Mechanical thresholds 
von Frey test 
Static mechanical withdrawal thresholds were assessed by applying von Frey hairs (Touch 
Test, Stoelting, IL, USA) to the plantar surface of the hind paw. Unrestrained animals were 
acclimatised in acrylic cubicles (8 x 5x 10 cm) on a wire mesh grid for 60 min prior to testing. 
Calibrated von Frey hairs (flexible nylon fibres of increasing diameter that exert defined levels 
of force) were applied to the plantar surface of the hind paw until the fibre bent. The hair was 
held in place for 3 secs or until the paw was withdrawn in a reflex not associated with 
movement or grooming. Each hair was applied 5 times to both the left and the right paw 
alternately, starting with the lowest force hair. Hairs of increasing force were applied in 
 sequence, 5 applications per hair. A positive response was recorded when a 40% withdrawal 
response occurred over 5 applications. 
 
Randall-Selitto test 
Mechanical nociceptive thresholds were evaluated using an Analgesy-Meter (Ugo Basile, 
Comerio, Italy).  Rats were gently held and incremental pressure (maximum 25 g) was applied 
onto the dorsal surface of the hind paw. The pressure required to elicit paw withdrawal, the 
paw pressure threshold, in g was determined. An average of three recordings were taken 
separated by at least 5 minutes. 
 
Thermal thresholds 
Hot plate- Hargreaves test 
Briefly, the rats were habituated for 10 minutes to an apparatus consisting of individual 
Plexiglas boxes on an elevated glass table. A mobile radiant heat source was located under the 
table and focused on the hind paw, and the paw withdrawal latencies were defined as the time 
taken by the rat to remove its hind paw from the heat source. The cut-off point was set at 25 s 
to prevent tissue damage. The apparatus was calibrated to give a paw withdrawal latency of 
approximately 15 s in naïve rats. An average of three recordings were taken separated by at 
least 5 minutes. 
 
Cold plate 
Withdrawal of the hind paw in response to painful cold stimulation was assessed using an 
Incremental Hot/Cold Plate (IITC Life Sciences) set at 4±0.1°C. Rats were lightly restrained 
and the hind paw was held with the plantar surface on the cold plate. The latency to withdraw 
the paw was measured to the nearest 0.01secs. To avoid tissue injury, the maximum latency 
 period permitted was 20 secs. An average of three recordings were taken separated by at least 
5 minutes. 
 
RNA extraction and Sequencing 
Total RNA isolation and RT-qPCR analysis 
Frozen micro dissected spinal cord samples were lysed with Teflon-glass homogenisers and 
QIAshredder columns (Qiagen). Total RNA was isolated with the Qiagen RNeasy® Mini kit. 
The RNA was assessed for purity and quantity using the Nanodrop 1000 spectrophotometer 
and assessed for quality on the Agilent Bioanalyzer 2100.  RNA was reverse transcribed with 
a QuantiTect® Reverse Transcription kit (Qiagen). Levels of BRCA1, TNFα and TNFR1 
expression were quantitated in triplicate, relative to GAPDH and triplicate non-template 
controls for each gene, by RT-qPCR analysis on a LightCycler® 480 instrument with 
LightCycler® SYBR® Green I Master reagent (Roche). Primer pairs used were; BRCA1 F: 
5’-AGGCAAGATCTCGAAGGAACCC-3’; R: 5’-AATCAGGGTCTCTGCTGGAGACTA-
3’; TNFα F: 5’-CTGTGCCTCAGCCTCTTCTC-3’; R: 5’-ACTGATGAGAGGGAGCCCAT-
3’; TNFR1 F: 5’-CCTCTCTCCCCTCGGCTTTA-3’; R: 5’-
CCCGGGTTAGAAAGGCTCAA-3’; GAPDH F: 5’-TGACCTCAACTACATGGTCTACA-
3’; R: 5’-GACTCCACGACATACTCAGCA-3’. RT-qPCR cycling parameters were optimised 
for each gene and were as follows:BRCA1, 400nM Forward and reverse primers, 45 cycles of 
95 °C 15 s; 60 °C 40 s; 72 °C 20 s. TNFα and TNFR1, 500nM forward and reverse primers, 45 
cycles of 95 °C 10 s; 60 °C 20 s; 72 °C 10 s. Amplicons were confirmed by analysis of melting 
peaks and agarose gel electrophoresis. 
 
 
 
 mRNA Library preparation 
Four hundred ng of intact high quality total RNA (RIN>7.9) from each sample was then used 
as input to generate libraries for RNA-sequencing using the NEBNext Ultra II Directional kit 
(NEB, Cat.no: E7760S) following the manufacturer’s recommendations. This protocol 
involved an initial step of mRNA selection using a poly-A isolation module (NEB, Cat.no: 
E7490) to select for mRNA with a mature polyA tail, followed by fragmentation prior to first 
cDNA synthesis and barcoding second-strand cDNA synthesised with indices for Illumina 
sequencing for final library amplification (10-cycles). The resulting libraries (342-421bp) were 
assessed on the Bioanalyzer 2100 for purity. The NEBNext Library Quant Kit for Illumina 
(NEB, Cat.no: E7630L) was used to calculate the quantity of each library. The quantification 
data was used to pool the libraries in equal molarity prior to performing a QC run on the MiSeq 
(MiSeq Reagent Kit v3 (150-cycle); Cat no: MS-102-3001). Further deep sequencing was 
performed on the pooled library over 2 lanes using a HiSeq4000 (by GENEWIZ) to generate 
roughly 26 million reads per sample. 
 
RNA-Seq Data Analysis 
Samples were aligned to the reference genome (Rattus_norvegicus Rnor_6.0.94) with 
Bowtie2(Langmead and Salzberg, 2012). Aligned sequenced reads per sample were associated 
to annotated genes with HTSeq (https://htseq.readthedocs.io/en/release_0.11.1/count.html), 
followed by an inter-sample quantile normalization to correct for technical differences. 
Differential expression analysis (relative to the samples issued from non-injured and vehicle 
treated animals) has been performed with Deseq2 (Love et al., 2014). Differentially expressed 
genes assessed in various conditions (non-injured +C286; Injured +vehicle; Injured +C286) 
were stratified over three major states (induced, repressed or non-differentially expressed) such 
that a total of 26 hypothetical combinatorial co-expression events were inferred. Among them, 
 only 8 appeared as biologically significant situations where the effect of the ligand C286 could 
be inferred (Figure 1G). To support this hypothesis, all combinatorial co-expression events 
were analyzed for Gene Ontology (GO) enrichment (DAVID bioinformatics resources),(Huang 
da et al., 2009) demonstrating relevant enrichment GO terms preferentially in the case of the 
selected biologically selected co-expression paths. 
 
Microglia cultures 
Primary mixed glial cultures were prepared as described previously (Goncalves et al., 2019b).  
Briefly, mixed glial cultures were obtained from the cortices of C57B/6 postnatal mice (P5–
P8). Cultures were maintained at 37 °C (5% CO2/95% O2) in medium containing 15% fetal 
bovine serum (Invitrogen) and 1% penicillin-streptomycin (Sigma Aldrich) for 10–14 days. 
Microglial cells were then harvested by forceful shaking for 1 min by hand and plated on poly-
d-lysine-coated glass coverslips or plastic six-well plates. To obtain reactive microglia, cells 
were treated with 100ng/ml lipopolysaccharides (LPS) for 3hr (Tarassishin et al., 2014) and 
then for another 3 hr with either: vehicle; C286 (10-7 M); KU55933 (Hickson et al., 2004) 
(1M, Abcam, ab120637) or C286 +KU55933.   
 
Immunochemistry and Antibodies 
Immunohistochemistry and cytochemistry were carried out as previously described (Goncalves 
et al., 2005). For the spinal cords: paraffin wax (Pwax) embedded tissues, were first dewaxed 
in xylene and 100% IMS, then heated in citric acid (10 mM, pH = 6), until boiling, then washed 
under a running tap for 5 min. For microglia cultures: cells were fixed for 15 min. with 4% 
PFA. Tissue sections or cells were washed 3x for 5 min each in PBS before incubation with 
primary antibody in PBS-0.02% Tween at 4ºC overnight. Primary antibody was removed by 
washing 3x for 5 min each in PBS. They were incubated in the secondary antibody for 1 hr. at 
 room temperature (RT) in PBS-0.02% Tween, and then washed in PBS 3x for 5 minutes. 
Antibodies used were: mouse monoclonal anti-βIII tubulin (G7121, Promega, 1:1000); goat 
polyclonal anti-Iba1 (ab107159, Abcam, 1:2,000); chicken polyclonal anti-Iba1 (ab139590, 
Abcam, 1:500); rabbit polyclonal anti-FZD10 (ab83044, Abcam, 1:500); rabbit polyclonal 
anti-BDNF (NBP1-46750, Novus Biologicals,1:1,000); chicken polyclonal anti-GFP 
(ab13970, Abcam, 1:400) mouse monoclonal anti-TNF (ab1793, Abcam, 1:500); rabbit 
polyclonal anti-TNFR1 (ab58436, Abcam, 1:500); rabbit polyclonal anti-NGF 9ab6199, 
Abcam, 1:100); sheep polyclonal anti-CGRP (BML-CA1137, ENZO, 1;500); rabbit polyclonal 
anti-BRCA1 (ab191042; Abcam, 1:50); rabbit polyclonal anti-H2AX (ab2893, Abcam, 
1:5,000); mouse monoclonal anti-pATM (sc-47739, Santa Cruz Biotechnology,1:50) ; mouse 
monoclonal anti-NeuN (MAB377, Millipore, 1:1000); rabbit monoclonal anti-NeuN (#12943, 
Cell Signaling Technology, 1:3000); rabbit polyclonal anti-P2XR4 (APR-024, alomone labs, 
1:20); rabbit polyclonal anti-Daxx (LS-B363, LSBio, 1:50). Secondary antibodies were 
AlexaFluor™ 594, AlexaFluor™ 488 (1:1000, Molecular Probes, Life Technologies) and 
AlexaFluor™ 647 (1:1000, Molecular Probes, Life Technologies). DAPI was used to stain 
nuclei (1 μg/mL, Sigma Aldrich).  
 
Immunochemistry quantification 
Quantification of protein levels by immunofluorescence (IF) was done as previously described 
(Herrmann et al., 2010).  In brief, positively stained areas were quantified as the pixels of 
immunoreactivity above a threshold level per unit area using the Zeiss Zen blue edition 
software. The threshold value was set to include fluorescent positive signal and to exclude 
background staining. Threshold values for a given section and stain remained the same 
throughout the study and the quantifications were done by an operator blinded to the treatments. 
 
 Confocal microscopy 
Multichannel fluorescence (DAPI–FITC–Texas Red filter set) images were captured using a 
Zeiss LSM 700 laser-scanning confocal microscope. For high magnification images, a 63 x oil-
immersion Aprochromat objective (Carl Zeiss) was used. Settings for gain, aperture, contrast 
and brightness were optimized initially, and held constant throughout each study so that all 
sections were digitized under the same conditions of illumination. Channels were imaged 
sequentially to eliminate bleed-through, and multichannel image overlays were obtained using 
Adobe Photoshop 7.0 (Adobe Systems).  
 
Western blotting 
Spinal cord proteins were isolated from the phenol fraction remaining after QIAzol RNA 
extraction, according to the Qiagen user-developed protocol RY16. Briefly, the phenolic phase 
was treated with ethanol and the proteins precipitated by isopropanol. Protein pellets were 
sequentially washed with 0.3M guanidine-hydrochloride in 95% ethanol and 100% ethanol, air 
dried, then resuspended in 10M urea, 50mM DTT in water. Protein concentrations were 
measured by Coomassie-Bradford assays and proteins were separated by SDS-PAGE from 
20µg aliquots loaded on to 12% (w/v) Bis-Tris polyacrylamide gels. For BDNF analysis the 
separated proteins were blotted to a 0.45µm pore size nitrocellulose membrane (BA85; 
Schleicher and Schuell) with a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad Laboratories). 
The membrane was incubated in Odyssey® Blocking Buffer (PBS) (LICOR Bioscience) for 1 
h at RT followed by an overnight incubation at 4°C with the primary antibody in blocking 
buffer. Anti-β-actin antibody was then added, for 1 h at room temperature (RT), after which 
the membrane was washed with PBS containing 0.1%v/v Tween-20 and incubated for a further 
1 h at RT with secondary antibodies in blocking buffer. Finally, the membrane was washed as 
before and simultaneously scanned at 700nm and 800nm using an Odyssey® protein detection 
 system (LICOR Bioscience). Proteins were quantified using Image Studio Lite software 
(LICOR Bioscience) and normalized against β-actin. For the detection of BRCA1, proteins 
were transferred to a Hybond™-ECL membrane (GE Healthcare). The membrane was cut at 
the 76kD marker and both sections incubated in a blocking buffer consisting of 1% (w/v) BSA 
in TBS-Tween-20 (0.1%, v/v) for 1 h at RT followed by an overnight incubation at 4°C with 
anti-BDNF antibody added to the top section only. The top membrane was washed with TBS-
Tween-20 (0.1% v/v) then incubated with a biotinylated secondary antibody for 1 h at RT, 
washed as before and incubated with ECL™ Western Blotting Detection Reagents (GE 
Healthcare). Proteins were visualised with the BioSpectrum Imaging system (UVP). The lower 
section of the membrane was incubated with a β-actin antibody for 1 h at RT followed by 
washing with TBS-Tween-20 (0.1% v/v) and incubation for a further at 1 h at RT with 
secondary antibodies in blocking buffer. β-Actin was visualised with the Odyssey® protein 
detection system (LICOR Bioscience) as above. Antibodies:  Rabbit polyclonal anti-BRCA1 
(ab191042, Abcam, 1:500); mouse monoclonal anti-BDNF (Ab205067, Abcam, 1:500); Rabbit 
polyclonal anti-β-actin (Ab8227, Abcam, 1:5000); Biotinylated Goat Anti-Rabbit IgG (BA-
1000, Vector Laboratories, 1:500); Alexa Fluor680 (1:5000, Invitrogen) and IR Dye 800CW 
(1:5000, LICOR Biosciences). 
 
Statistical analysis  
Data and statistical analysis comply with the recommendations on experimental design and 
analysis in pharmacology (Curtis and Abernethy, 2015). Data analysis was performed in a 
blinded fashion.  All statistical analysis was performed using Sigma Stat Software (SPSS 
Software Ltd, Birmingham, UK) using unpaired t-tests and one-way ANOVA with Pairwise 
Multiple Comparison Procedures (Tukey Test), or two-way ANOVA with Pairwise Multiple 
Comparison Procedures (Holm-Sidak method) as indicated in the Figure legends. *p ≤ 0.05, 
 **p ≤ 0.01, ***p ≤ 0.001. Exact p values are shown when p> 0.001. n represents the number 
of biological replicates. Experiments were repeated to ensure reproducibility of the 
observations. No statistical methods were used to predetermine sample size. 
 
Data and Software Availability 
Raw and processed transcriptome datasets are available under the GEO accession number 
(GSE135080) and the Mendeley repository  Mendeley 
Data, v1 http://dx.doi.org/10.17632/kjvs5vgkbf.1DOI . 
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